natgillin/translations-raw huggingface dataset:
Drug-drug interactions 
Medsebojno delovanje zdravil
A thorough QT (TQT) study (n = 164 healthy male and n = 153 healthy female volunteers with a mean age of 33 years) evaluated the effect of repeat oral dosing of mirabegron at the indicated dose (50 mg once daily) and two supra-therapeutic doses (100 and 200 mg once daily) on the QTcI interval. 
Ocenila je vpliv večkratne peroralne uporabe mirabegrona v indiciranem odmerku (50 mg enkrat na dan) in v dveh supraterapevtskih odmerkih (100 mg in 200 mg enkrat na dan) na interval QTcI.
Following single dose administration of 100 mg Betmiga in volunteers with mild renal impairment (eGFR-MDRD 60 to 89 mL/min/1.73 m2), mean mirabegron Cmax and AUC were increased by 6% and 31% relative to volunteers with normal renal function. 
Pri prostovoljcih z blago okvaro ledvic (eGFR-MDRD od 60 do 89 ml/min/1,73 m2 po) sta bili povprečna Cmax in AUC zdravila Betmiga po enkratnem odmerku 100 mg za 6 % (Cmax) oz. 31 %
How to store Betmiga 
Shranjevanje zdravila Betmiga
Mean number of incontinence episodes per 24 hours (FAS-I) (Co-primary) 
Povprečno število epizod inkontinence na 24 ur (FAS-I) (soprimarni)
Vaginal infection Cystitis 
Infekcijske in parazitske bolezni okužba sečil okužba nožnice cistitis
What you need to know before you take Betmiga 3. 
Kaj je zdravilo Betmiga in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Betmiga Kako jemati zdravilo Betmiga
Mean number of micturitions per 24 hours (FAS) (Co-primary) 
Povprečno število mikcij na 24 ur (FAS) (soprimarni)
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR BLISTERS 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA ZA PLASTENKE
Blood pressure increased 
Vpliv na očesni tlak
In volunteers with severe renal impairment (eGFR-MDRD 15 to 29 mL/min/1.73 m2), mean Cmax and AUC values were 92% and 118% higher. 
Pri prostovoljcih s hudo okvaro ledvic (eGFR-MDRD od 15 do 29 ml/min/1,73 m2) je bila povprečna
Mean baseline Mean change from baseline† Mean difference from placebo† 
Povprečna sprememba od izhodišča† Povprečna razlika od placeba† -
No clinically relevant interactions have been observed when mirabegron was co-administered with therapeutic doses of solifenacin, tamsulosin, warfarin, metformin or a combined oral contraceptive medicinal product containing ethinylestradiol and levonorgestrel. 
Med sočasno uporabo mirabegrona s terapevtskimi odmerki solifenacina, tamsulozina, varfarina,
Mild 
blaga
For both males and females administered mirabegron at 50 mg and 
Ne pri moških ne pri ženskah, ki so prejeli 50 mg in
Mean change from baseline† -0.92 Mean difference from placebo† -95% Confidence Interval 
Povprečna sprememba od izhodišča† Povprečna razlika od placeba† 95 % interval zaupanja Vrednost p
Betmiga 50 mg prolonged-release tablets mirabegron 
Betmiga 50 mg tablete s podaljšanim sproščanjem mirabegron
Betmiga 25 mg prolonged-release tablets mirabegron 
Betmiga 25 mg tablete s podaljšanim sproščanjem mirabegron
Mean change from baseline† -0.93 Mean difference from placebo† -95% Confidence Interval 
Placeb o Mirabegro n 50 mg sprememba od izhodišča† Povprečna razlika od placeba† 95 % interval zaupanja Vrednost p
Uncommon side effects (may affect up to 1 in 100 people) 
Občasni neželeni učinki (pojavijo se lahko pri največ 1 od 100 bolnikov) - okužba sečnega mehurja (cistitis)
Insomnia* Confusional state* 
stanje zmedenosti*
Betmiga 25 mg prolonged-release tablets 
Betmiga 25 mg tablete s podaljšanim sproščanjem
Betmiga 50 mg prolonged-release tablets 
Betmiga 50 mg tablete s podaljšanim sproščanjem
The frequency of urinary tract infections was 2.9% in patients receiving Betmiga 50 mg. Urinary tract infections led to discontinuation in none of the patients receiving Betmiga 50 mg. Serious adverse reactions included atrial fibrillation (0.2%). 
Pri bolnikih, ki so prejemali 50 mg zdravila Betmiga, je bila pogostnost okužb sečil 2,9 %.
Urinary retention* 
Bolezni sečil zastajanje urina*
Table 4: Co-primary efficacy endpoints for patients with prior OAB antimuscarinic therapy 
Preglednica 4: Soprimarni opazovani dogodki učinkovitosti pri bolnikih, ki so zaradi PASM
Caution is also advised if mirabegron is co-administered with CYP2D6 substrates that are individually dose titrated. 
Mirabegron so preučili pri zdravih osebah, ki so genotipsko slabi metabolizatorji substratov CYP2D6 (to je nadomestni kazalnik zavrtja CYP2D6).
Taking into account the PRAC Assessment Report on the PSUR(s) for mirabegron, the scientific conclusions of CHMP are as follows: 
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za mirabegron je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke: Imetnik dovoljenja za promet je pregledal komulativne primere stanja zmedenosti z uporabo visokonivojskega skupnega izraza (HLGT) "deliriji" (vključno z zmedenostjo).
The most common adverse reactions reported for patients treated with Betmiga 50 mg during the three 12-week phase 3 double blind, placebo controlled studies are tachycardia and urinary tract infections. 
dvojno slepih, s placebom kontroliranih študijah 3. faze sta bila tahikardija in okužbe sečil.
25 mg 
25 mg zmerna
Betmiga may increase your chances of not being able to empty your bladder if you have bladder outlet obstruction or if you are taking other medicines to treat overactive bladder. 
- zmedenost Če imate zaporo sečnega mehurja ali jemljete druga zdravila za zdravljenje prekomerno aktivnega sečnega mehurja, lahko zdravilo Betmiga poviša nezmožnost praznjenja mehurja.
Oval, brown tablet, debossed with the company logo and “325” on the same side. 
Betmiga 25 mg tablete Ovalna, rjava tableta z vtisnjenima oznakama logo podjetja in “325” na isti strani.
Effect on intraocular pressure (IOP) 
Vpliv na srčno frekvenco in krvni tlak pri bolnikih s prekomerno aktivnim sečnim mehurjem (PASM)
Oval, yellow tablet, debossed with the company logo and “355” on the same side. 
Betmiga 50 mg tablete Ovalna, rumena tableta z vtisnjenima oznakama logo podjetja in “355” na isti strani.
Betmiga is not recommended in patients with severe renal impairment (GFR 15 to 29 mL/min/1.73 m2) or patients with moderate hepatic impairment (Child-Pugh Class B) concomitantly receiving strong CYP3A inhibitors (see sections 4.2 and 4.4). 
Zdravilo Betmiga ni priporočljivo za bolnike s hudo okvaro ledvic (hitrost glomerularne filtracije od 15 do 29 ml/min/1,73 m2) in bolnike z zmerno okvaro jeter (Child-Pugh B),
Leukocytoclastic vasculitis Purpura 
Biocodex UABTel.
Hepatic impairment 
Psihiatrične motnje nespečnost*
- if you have an ECG (heart tracing) abnormality known as QT prolongation or you are taking any medicine known to cause this such as o medicines used for abnormal heart rhythm such as quinidine, sotalol, procainamide, ibutilide, flecainide, dofetilide, and amiodarone; o medicines used for allergic rhinitis; 
prokainamid, ibutilid, flekainid, dofetilid in amiodaron; o zdravila za zdravljenje alergijskega rinitisa;
Hepatic impairment(2) 
25 mg uporaba ni priporočljiva okvara jeter(2)
Betmiga at doses of 50 mg and 100 mg once daily for 12 weeks in men with lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO) showed no effect on cystometry parameters and was safe and well tolerated. 
(LUTS - lower urinary tract symptoms) in obstrukcijo iztoka iz mehurja (BOO) zdravilo Betmiga ni vplivalo na cistometrične parametre.
Moderate 
Urodinamika
Nervous system disorders 
Iz živčnih končičev se sprošča noradrenalin.
Mean change from baseline† Mean difference from placebo† (95% CI) p-value 
Povprečna izhodiščna vrednost Povprečna sprememba od izhodišča† Povprečna razlika od placeba† (95% IZ)
Further information on Apealea can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/apealea. 
Nadaljnje informacije o zdravilu Apealea so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/apealea.
What measures are being taken to ensure the safe and effective use of Apealea? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Apealea?
Other information about Apealea 
Druge informacije o zdravilu Apealea
The average length of time that patients lived without their disease coming back yet again was 10.3 months with Apealea, and 10.1 months with conventional paclitaxel. 
Povprečna doba, ki so jo bolnice preživele brez naknadne ponovitve bolezni je bila z zdravilom Apealea 10,3 meseca, z običajnim paklitakselom pa 10,1 meseca.
The most common side effects with Apealea (which may affect more than 1 in 10 people) are neutropenia (low numbers of white blood cells called neutrophils), stomach and gut disorders such as diarrhoea, nausea (feeling sick) and vomiting, peripheral neuropathy (nerve damage in hands and feet), joint and muscle pain, and reactions such as redness, soreness and inflammation of the veins at the site of infusion. 
Najpogostejši neželeni učinki (ki lahko prizadenejo več kot 1 osebo od 10) so nevtropenija (nizko število belih krvničk imenovanih nevtrofilci), težave z želodcem in črevesjem, kot je driska, navzeja (siljenje na bruhanje) in bruhanje, periferna nevropatija (poškodba živcev v dlaneh in stopalih), bolečine v sklepih in mišicah ter reakcije, kot je rdečica, bolečina in vnetje žil na mestu infundiranja.
As for all medicines, data on the use of Apealea are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Apealea stalno spremljajo.
It belongs to the group of cancer medicines known as the ‘taxanes'. 
Spada v skupino zdravil za zdravljenje raka, imenovanih taksani.
By keeping this structure intact the cells cannot divide and they eventually die. 
Z ohranjanjem celičnega skeleta se celice ne morejo deliti in sčasoma odmrejo.
The Agency therefore decided that Apealea's benefits are greater than its risks and it can be authorised for use in the EU. 
Agencija je zato zaključila, da so koristi zdravila Apealea večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Apealea have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Apealea upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
The medicine can only be obtained with a prescription and should be given under the supervision of a specialist in the treatment of cancer. 
Predpisovanje in izdaja zdravila je le na recept, dajati pa ga je treba pod nadzorom zdravnika specialista za zdravljenje raka.
An overview of Apealea and why it is authorised in the EU 
Pregled zdravila Apealea in zakaj je odobreno v EU
What benefits of Apealea have been shown in studies? 
Kakšne koristi je zdravilo Apealea izkazalo v študijah?
What are the risks associated with Apealea? 
Kakšna tveganja so povezana z zdravilom Apealea?
For more information about using Apealea, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Apealea glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Why is Apealea authorised in the EU? 
Zakaj je zdravilo Apealea odobreno v EU?
stage of cell division in which the cell's internal ‘skeleton' is dismantled to allow the cell to divide. 
delitve, v kateri se notranji „skelet“ celice običajno razgradi, kar ji omogoči delitev.
Supportive data from the study showed that the average time that patients lived after treatment was 25.7 months among those given Apealea and 24.8 months for those given conventional paclitaxel. 
Podporni podatki iz študije so pokazali, da je bilo obdobje preživetja bolnic po zdravljenju 25,7 meseca pri bolnicah, ki so prejele zdravilo Apealea, in 24,8 meseca pri bolnicah, ki so prijele običajni paklitaksel.
The dose of Apealea is 250 mg per square metre (calculated based on height and body weight) and is given by infusion over about 1 hour, once every 3 weeks, for 6 cycles of treatment. 
Odmerek zdravila Apealea je 250 mg na kvadratni meter (izračunano na podlagi višine in telesne mase) in se daje šestkrat zaporedoma kot enourna infuzija vsake tri tedne.
Side effects reported with Apealea are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Apealea, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
While the new formulation might be associated with more infusion site reactions, and studies suggested stronger effects on blood cells and the gut, these were considered manageable and the overall benefits and risks are consistent with those of other paclitaxel medicines. 
Novo formulacijo je sicer mogoče povezati z večjim številom reakcij na mestu infundiranja, študije pa so opozorile tudi na večje učinke na krvne celice in črevesje, a so bili ti neželeni učinki zdravila obvladljivi, splošne koristi in tveganja pa so primerljivi z drugimi zdravili, ki vsebujejo paklitaksel.
What is Apealea and what is it used for? 
Kaj je zdravilo Apealea in za kaj se uporablja?
The active substance in Apealea, paclitaxel, is a cancer medicine that has been used in the EU for many years. 
Učinkovina v zdravilu Apealea, paklitaksel, je zdravilo za zdravljenje raka, ki se že več let uporablja v EU.
Apealea has been shown to be as effective as a conventional formulation of paclitaxel in one main study involving further treatment of 789 women whose ovarian, fallopian tube or peritoneal cancer had come back. 
Zdravilo Apealea se je izkazalo kot enako učinkovito kot ustaljena formulacija paklitaksela v glavni študiji, v katero je bilo vključenih 789 žensk, pri katerih se je rak jajčnikov ali jajcevodov oziroma peritonealni rak ponovil.
The European Medicines Agency considered that Apealea was as effective as conventional paclitaxel, and could be a valuable alternative in combination with carboplatin. 
Evropska agencija za zdravila je zaključila, da je zdravilo Apealea po učinkovitosti primerljivo z običajnim paklitakselom in je lahko koristna zamenjava v kombinaciji s karboplatinom.
Doses may be delayed or reduced by the doctor, or treatment may be stopped, if severe side effects occur; doses should also be reduced in patients with moderate or severe reduction in liver function. 
Če se pojavijo resni neželeni učinki, lahko zdravnik odmerek preloži ali zmanjša oziroma zdravljenje ustavi; odmerke je treba prav tako zmanjšati pri bolnicah z zmernimi ali hudimi motnjami delovanja jeter.
Apealea must not be used in patients who are breast feeding or those who already have low levels of neutrophils in the blood. 
Zdravila Apealea ne smejo uporabljati doječe matere in osebe, ki že imajo nizko število nevtrofilcev.
Apealea is available as a powder to make up a solution for infusion (drip) into a vein. 
Zdravilo Apealea je na voljo v obliki praška za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
Apealea is a cancer medicine used to treat women with cancer of the ovary or surrounding structures (the fallopian tube that connects the ovary to the womb, or the peritoneum, the membrane that lines the abdomen). 
Apealea je zdravilo za zdravljenje raka, ki se uporablja pri odraslih ženskah z rakom jajčnikov ali sosednjih struktur (jajcevodov, ki povezujejo jajčnike z maternico) in peritonelanega raka (raka membrane, ki ovija trebušno votlino).
Apealea is given along with a platinum-based medicine, carboplatin, to patients whose disease responds to platinum-based cancer medicines and has come back after initial treatment. 
Zdravilo Apealea se daje skupaj z zdravilom na osnovi platine, karboplatinom, in sicer bolnicam, katerih rak se odziva na zdravila za zdravljenje raka na osnovi platine in se je ponovil.
Patients are also treated with a platinum-based medicine, carboplatin. 
Bolnice se zdravijo tudi z zdravilom na osnovi platine, karboplatinom.
Apealea contains the active substance paclitaxel. 
Zdravilo Apealea vsebuje učinkovino paklitaksel.
For the full list of side effects of Apealea, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Apealea, glejte navodilo za uporabo.
How is Apealea used? 
Kako se zdravilo Apealea uporablja?
Patients also received a platinum-based cancer medicine, carboplatin. 
Bolnice so prejele tudi zdravilo na osnovi platine, karboplatin.
The paclitaxel in Apealea is formulated in tiny particles, called micelles, to help it dissolve in the infusion solvent. 
Učinkovina paklitaksel v zdravilu Apealea je v obliki majhnih delcev, imenovanih micele, ki pripomorejo k boljšemu topljenju v topilu za infundiranje.
How does Apealea work? 
Kako zdravilo Apealea deluje?
-1 Live avian infectious bronchitis virus, strain D388: 104.0 - 105.5 EID50*/dose * 50% egg infective dose 
-1 živi virus kužnega bronhitisa za perutnino D388 104.0 - 105.5 EID50*/odmerek 1 50-odstotni odmerek za embrionirana kokošja jajca
-1 Lyophilisate and solvent for oculonasal suspension 
-1 Liofilizat in topilo za okulonazalno suspenzijo
Solvent: 35 ml 
Topilo 35 ml
Solvent: vial (LDPE) 
Topilo: viala (LDPE)
10 lyophilisate cups + 10 solvent vials 
10 vsebnikov liofilizata + 10 vial topila
EU (MA) number Invented name 
EU številka Izmišljeno ime Jakost Farmacevtska oblika
Lyophilisate: 1,000 doses 
Liofilizat: 1000 odmerkov
Packaging Content Package size Withdrawal period 
Velikost pakiranja
10 cups 
Ovojnina
Chicken Oculonasal use Lyophilisate: cup (Alu/PP); 
Liofilizat: vsebnik (Al/PP)
It is available as tablets (2.5, 5, 10 and 20 mg). 
Na voljo je v obliki tablet (2,5, 5, 10 in 20 mg).
The main measure of effectiveness was the improvement in symptoms after 12 weeks. 
Glavno merilo učinkovitosti je bilo izboljšanje simptomov po 12 tednih.
The European Commission granted a marketing authorisation valid throughout the European Union for Cialis on 12 November 2002. 
Evropska komisija je dovoljenje za promet z zdravilom Cialis, veljavno po vsej Evropski uniji, izdala 12. novembra 2002.
What measures are being taken to ensure the safe and effective use of Cialis? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Cialis?
A doctor should consider the potential risks of sexual activity in men who have cardiovascular disease. 
Zdravnik mora upoštevati morebitna tveganja pri spolni aktivnosti moških, ki imajo srčno-žilne bolezni.
The full EPAR for Cialis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Cialis je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Cialis. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Cialis.
A risk management plan has been developed to ensure that Cialis is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Cialis je bil pripravljen načrt obvladovanja tveganj.
For more information about treatment with Cialis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Cialis preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Other information about Cialis 
Druge informacije o zdravilu Cialis
The CHMP decided that Cialis's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Cialis večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Once-a-day dosing of Cialis was studied in three further studies lasting 12 to 24 weeks and involving a total of 853 patients. 
Enkrat dnevno odmerjanje zdravila Cialis so nadalje proučevali v treh dodatnih študijah, ki so trajale od 12 do 24 tednov in v katerih je sodelovalo skupaj 853 bolnikov.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cialis. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
What benefit has Cialis shown during the studies? 
Kakšne koristi je zdravilo Cialis izkazalo med študijami?
Overall, in the studies of general populations, 81% of patients reported that Cialis ‘on demand' improved their erections as compared to 35% of those taking placebo. 
Na splošno je v študijah, izvedenih med splošno populacijo, 81 % bolnikov poročalo, da je zdravilo Cialis, vzeto „po potrebi“, izboljšalo njihovo erekcijo, v primerjavi s 35 % bolnikov, ki so jemali placebo.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom medicine should be taken around the same time every day and the appropriateness of the once-a-day dosing should be re-assessed regularly. 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom dobro ga bolnik prenaša.
Because Cialis has not been studied in patients who have had a heart attack within the last three months or a stroke within the last six months, or those who have high blood pressure or heart disorders (irregular heart beat), these men should not use the medicine. 
Zdravilo Cilais ni bilo raziskano pri bolnikih, ki so v zadnjih treh mesecih doživeli srčni infarkt ali možgansko kap v zadnjih šestih mesecih, ali pri bolnikih, ki imajo visok krvni tlak ali srčna obolenja (nepravilno bitje srca), zato ti bolniki zdravila ne smejo uporabljati.
One of these studies contained only diabetic men. 
V eni študiji so sodelovali samo moški s sladkorno boleznijo.
It must also not be taken by patients who have ever had loss of vision because of a problem with blood flow to the nerve in the eye (non-arteritic anterior ischemic optic neuropathy, NAION). 
Prav tako ga ne smejo jemati bolniki, ki so kadar koli imeli težave z vidom zaradi dotoka krvi v očesni živec (nearteritična anteriorna ishemična optična nevropatija ali NAION).
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Cialis, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Patients taking Cialis once a day at doses of 2.5 or 5 mg also reported improved erections compared with those taking placebo. 
Tudi bolniki, ki so zdravilo Cialis jemali enkrat na dan v odmerku 2,5 ali 5 mg, so poročali o izboljšanju erekcije v primerjavi s tistimi, ki so jemali placebo.
In all studies, the effects of Cialis were compared with those of placebo (a dummy treatment), and the main measure of effectiveness was the ability to get and maintain an erection. 
V vseh študijah so učinke zdravila Cialis primerjali z učinki placeba (zdravila brez zdravilne učinkovine), glavno merilo učinkovitosti pa je bila sposobnost doseči in obdržati erekcijo.
For one of the questionnaires, where the maximum score is 30, patients who recorded scores of about 15 before treatment, recorded scores of 22.6 or 25 after receiving Cialis 10 mg or 20 mg, respectively. 
V enem od vprašalnikov, kjer je bilo najvišje možno število točk 30, so bolniki, ki so imeli pred zdravljenjem 15 točk, po jemanju 10-miligramskega odmerka zdravila Cialis dosegli 22,6 točk oziroma 25 točk po jemanju 20-miligramskega odmerka.
The most common side effects with Cialis are headache, dyspepsia (indigestion), back pain and myalgia (muscle pain), which are more common at higher doses. 
Najpogostejši neželeni učinki zdravila Cialis so glavobol, dispepsija (prebavne motnje), bolečine v hrbtu in mialgija (bolečine v mišicah), ki pa so pogostejši pri večjih odmerkih.